Autolus Therapeutics (AUTL) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Autolus Therapeutics is the larger company by market cap ($241.7 million vs $228.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | SCTX |
|---|---|---|
| Share price | $0.9073 | $12.07 |
| Market cap | $241.65M | $228.58M |
| 1-day change | -7.38% | -8.70% |
| YTD return | -54.41% | — |
| 1-year return | -26.24% | — |
| 5-year return | -85.51% | — |
| EPS (TTM) | $-0.96 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.39M | — |
| Revenue growth (YoY) | +644.94% | — |
| Net income (latest FY) | $-287.53M | — |
| Gross margin | -27.83% | — |
| Operating margin | -358.87% | — |
| Net margin | -381.40% | — |
| 52-week high | $2.58 | $39.60 |
| 52-week low | $0.896 | $12.00 |
| Distance from 52-week high | -64.83% | -69.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +821.42% | +372.25% |
| Average volume | 2.07M | 403.27K |
| Shares outstanding | 266.34M | 18.94M |
| Employees | 752 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
AUTL vs SCTX FAQ
Which is bigger, Autolus Therapeutics or Scribe Therapeutics?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $228.58M for Scribe Therapeutics (SCTX).
Are Autolus Therapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.